Skip to main content

Advertisement

SpringerLink
Log in

The Evolving Cardiovascular Disease Risk Scores for Persons with Diabetes Mellitus

  • Diabetes and Cardiovascular Disease (ND Wong, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

We briefly introduce the concept and use of cardiovascular disease (CVD) risk scores and review the methodology for CVD risk score development and validation in patients with diabetes. We also discuss CVD risk scores for diabetic patients that have been developed in different countries.

Recent Findings

Patients with diabetes have a gradient of CVD risk that needs to be accurately assessed. Numerous CVD risk scores for diabetic patients have been created in various settings. The methods to develop risk scores are highly diverse and each choice has its own pros and cons. A well-constructed risk score for diabetic patients may be advocated by guidelines and adopted by healthcare providers to help determine preventive strategies. New risk factors are being investigated in order to improve the predictive accuracy of current risk scores.

Summary

A suitable CVD risk score for the diabetes population should be accurate, low-cost, and beneficial to outcome. While the performance (accuracy) has all been internally validated, validation on external populations is still needed. Cost-effectiveness and clinical trials demonstrating improvement in outcomes are limited and should be the target of future research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care. 1998;21(7):1138–45.

    Article  CAS  Google Scholar 

  2. Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres: the World Health Organisation multinational study of vascular disease in diabetics. Diabetologia. 1985;28:615–40.

    Article  Google Scholar 

  3. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Shairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–86.

    Article  CAS  Google Scholar 

  4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.

    Article  CAS  Google Scholar 

  5. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26:142–8.

    Article  CAS  Google Scholar 

  6. Howard BV, Best LG, Galloway JM, Howard WJ, Jones K, Lee ET, et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care. 2006;29:391–7.

    Article  Google Scholar 

  7. Zhao Y. Cardiovascular risk assessment and screening in diabetes. Cardiovasc Endocrinol Metab. 2017;6(1):17–22.

    Article  CAS  Google Scholar 

  8. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham study. Am J Cardiol. 1976;38(1):46–51.

    Article  CAS  Google Scholar 

  9. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care the Framingham heart study. Circulation. 2008;117(6):743–53.

    Article  Google Scholar 

  10. Conroy RM, Pyörälä K, Fitzgerald AE, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.

    Article  CAS  Google Scholar 

  11. World Health Organization. WHO/ISH cardiovascular risk prediction charts. Prevention of cardiovascular disease: guideline for assessment and management of cardiovascular risk [cited 2018 Aug 12]. Geneva: WHO; 2007.

    Google Scholar 

  12. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297(6):611–9.

    Article  CAS  Google Scholar 

  13. Stevens RJ, Kothari V, Adler AI, Stratton IM. United Kingdom prospective diabetes study (UKPDS) group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101(6):671–9.

    Article  Google Scholar 

  14. Poppe KK, Doughty RN, Wells S, Gentles D, Hemingway H, Jackson R, Kerr AJ. Developing and validating a cardiovascular risk score for patients in the community with prior cardiovascular disease. Heart. 2017;103(12):891–892.

    Article  Google Scholar 

  15. Yang X, Li J, Hu D, Chen J, Li Y, Huang J, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese PopulationClinical perspective: the China-PAR project (prediction for ASCVD risk in China). Circulation. 2016;134(19):1430–40.

    Article  Google Scholar 

  16. Jee SH, Jang Y, Oh DJ, Oh BH, Lee SH, Park SW, et al. A coronary heart disease prediction model: the Korean heart study. BMJ Open. 2014;4(5):e005025.

    Article  Google Scholar 

  17. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–59.

    Article  Google Scholar 

  18. Stone NJ, Robinson JG, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 part B):2889–934.

    Article  Google Scholar 

  19. Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am J Epidemiol. 2011;174(5):613–20.

    Article  Google Scholar 

  20. Kengne AP, Masconi K, Mbanya VN, Lekoubou A, Echouffo-Tcheugui JB, Matsha TE. Risk predictive modelling for diabetes and cardiovascular disease. Crit Rev Clin Lab Sci. 2014;51(1):1–2.

    Article  CAS  Google Scholar 

  21. D'Agostino RB Sr, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: insights from Framingham. Glob Heart. 2013;8(1):11–23.

    Article  Google Scholar 

  22. Kengne AP, Patel A, Colagiuri S, et al. The Framingham and UK prospective diabetes study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the action in diabetes and vascular disease: Preterax and Diamicron-MR controlled evaluation (ADVANCE) study. Diabetologia. 2010;53:821–31.

    Article  CAS  Google Scholar 

  23. Echouffo-Tcheugui JB, Kengne AP. Comparative performance of diabetes-specific and general population-based cardiovascular risk assessment models in people with diabetes mellitus. Diabetes Metab. 2013;39(5):389–96.

    Article  Google Scholar 

  24. •• Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and valudation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 2017;5:788–98 The RECODe risk scoring system predicts risk for the whole spectrum of diabetes macrovascular and microvascular complications and may better help pick out the high-risk for a specific type of complications among type 2 diabetes patients.

    Article  Google Scholar 

  25. Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil. 2011;18(3):393–8.

    Article  Google Scholar 

  26. Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus. Circulation. 2016;133(11):1058–66.

    Article  Google Scholar 

  27. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjörnsdottir S. Swedish National Diabetes Register. A new model for 5-year risk of cardiovascular disease in type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med. 2011;28(10):1213–20.

    Article  CAS  Google Scholar 

  28. Resl M, Clodi M, Vila G, Luger A, Neuhold S, Wurm R, Adlbrecht C, Strunk G, Fritzer-Szekeres M, Prager R, Pacher R. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes. Heart. 2016;102(24):1963–1968.

    Article  CAS  Google Scholar 

  29. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788–95.

    Article  CAS  Google Scholar 

  30. Yeboah J, Erbel R, Delaney JC, Nance R, Guo M, Bertoni AG, et al. Development of a new diabetes risk prediction tool for incident coronary heart disease events: the multi-ethnic study of atherosclerosis and the Heinz Nixdorf recall study. Atherosclerosis. 2014;236(2):411–7.

    Article  CAS  Google Scholar 

  31. Knowles JW, Ashley EA. Cardiovascular disease: the rise of the genetic risk score. PLoS Med. 2018;15(3):e1002546.

    Article  Google Scholar 

  32. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, et al. Genomic risk prediction of coronary artery disease in nearly 500,000 adults: implications for early screening and primary prevention. BioRxiv. 2018;1:250712.

    Google Scholar 

  33. Wilson PW, D’ Agostino RB, Belanger AM, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.

    Article  CAS  Google Scholar 

  34. Pepe MS, Kerr KF, Longton G, Wang Z. Testing for improvement in prediction model performance. Stat Med. 2013;32(9):1467–82.

    Article  Google Scholar 

  35. Pepe MS, Fan J, Feng Z, Gerds T, Hilden J. The net reclassification index (NRI): a misleading measure of prediction improvement even with independent test data sets. Stat Biosci. 2015;7(2):282–95.

    Article  Google Scholar 

  36. Van Dieren S, Beulens JW, Kengne AP, Peelen LM, Rutten GE, Woodward M, et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart. 2012;98:360–9.

    Article  Google Scholar 

  37. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom prospective diabetes study: UKPDS 82. Diabetologia. 2013;56(9):1925–33.

    Article  CAS  Google Scholar 

  38. Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate future risk of heart failure in patients with diabetes: a prospective cohort study. BMJ Open. 2015 Sep 1;5(9):e008503.

    Article  Google Scholar 

  39. Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS. Atherosclerosis risk in communities study investigators. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care. 2003;26(10):2777–84.

    Article  Google Scholar 

  40. Lagani V, Chiarugi F, Thomson S, Fursse J, Lakasing E, Jones RW, et al. Development and validation of risk assessment models for diabetes-related complications based on the DCCT/EDIC data. J Diabetes Complicat. 2015;29(4):479–87.

    Article  Google Scholar 

  41. Goliasch G, Silbernagel G, Kleber ME, Grammer TB, Pilz S, Tomaschitz A, et al. Refining long-term prediction of cardiovascular risk in diabetes–the VILDIA score. Sci Rep. 2017;7(1):4700.

    Article  Google Scholar 

  42. Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine. Circulation. 2016;133(11):1058–66.

    Article  Google Scholar 

  43. • Wan EYF, Fong DYT, Fung CSC, Yu EYT, Chin WY, Chan AKC, et al. Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with type 2 diabetes mellitus: A population-based retrospective cohort study. Diabetes Obes Metab. 2018;(2):309–318. https://doi.org/10.1111/dom.13066. This CVD risk score for Chinese diabetic population is the latest DM-specific risk score with the most contemporary cohort.

    Article  Google Scholar 

  44. Woodward M, Hirakawa Y, Kengne AP, Matthews DR, Zoungas S, Patel A, et al. Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. Diabetes Obes Metab. 2016;18(3):289–94.

    Article  CAS  Google Scholar 

  45. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK prospective diabetes study risk engine. Stroke. 2002;33(7):1776–81.

    Article  Google Scholar 

  46. Lundqvist A, Carlsson KS, Johansen P, Andersson E, Willis M. Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations. PLoS One. 2014;9(10):e110235.

    Article  Google Scholar 

  47. Parrinello CM, Matsushita K, Woodward M, Wagenknecht LE, Coresh J, Selvin E. Risk prediction of major complications in individuals with diabetes: the a therosclerosis R isk in C ommunities S tudy. Diabetes Obes Metab. 2016;18(9):899–906.

    Article  CAS  Google Scholar 

  48. Basu S, Sussman JB, Berkowitz SA, Hayward RA, Bertoni AG, Correa A, Mwasongwe S, Yudkin JS. Validation of risk equations for complications of type 2 diabetes (RECODe) using individual participant data from diverse longitudinal cohorts in the US. Diabetes care. 2017:dc172002.

  49. Zethelius B, Eliasson B, Eeg-Olofsson K, Svensson AM, Gudbjörnsdottir S, Cederholm J. A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract. 2011;93(2):276–84. https://doi.org/10.1016/j.diabres.2011.05.037.

    Article  Google Scholar 

  50. Read SH, van Diepen M, Colhoun HM, Halbesma N, Lindsay RS, McKnight JA, McAllister DA, Pearson ER, Petrie JR, Philip S, Sattar N. Performance of cardiovascular disease risk scores in people diagnosed with type 2 diabetes: external validation using data from the national Scottish diabetes register. Diabetes care. 2018:dc180578.

  51. Jardine MJ, Hata J, Woodward M, Perkovic V, Ninomiya T, Arima H, et al. Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis. 2012;60(5):770–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology, University of California Los Angeles Fielding School of Public Health, 650 Charles E Young Drive, Los Angeles, CA, 90095, USA

    Yanglu Zhao & Nathan D. Wong

  2. Heart Disease Prevention Program, University of California, Irvine, Irvine, CA, USA

    Yanglu Zhao & Nathan D. Wong

Authors
  1. Yanglu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathan D. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yanglu Zhao.

Ethics declarations

Conflict of Interest

Dr. Zhao has no conflicts to report.

Dr. Wong receives research funding from Amgen, Boehringer-Ingelheim, Amarin, and Pfizer; is a consultant for Astra-Zeneca and Akcea; and is on the speaker’s bureau for Sanofi.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Diabetes and Cardiovascular Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, Y., Wong, N.D. The Evolving Cardiovascular Disease Risk Scores for Persons with Diabetes Mellitus. Curr Cardiol Rep 20, 126 (2018). https://doi.org/10.1007/s11886-018-1069-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-018-1069-5

Keywords

Search

Navigation